Oncotarget

Reviews:

This article has been corrected. Correction in: Oncotarget. 2018; 9:34856.

Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells

Joshua C. Curtin and Matthew V. Lorenzi _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2010; 1:563-577. https://doi.org/10.18632/oncotarget.191

Metrics: PDF 9810 views  |   HTML 7598 views  |   ?  


Abstract

Received: August 8, 2010, Accepted: October 27, 2010, Published: October 30, 2010

Cancer stem cells (CSCs) represent a unique subset of cells within a tumor that possess self-renewal capacity and pluripotency, and can drive tumor initiation and maintenance. First identified in hematological malignancies, CSCs are now thought to play an important role in a wide variety of solid tumors such as NSCLC, breast and colorectal cancer. The role of CSCs in driving tumor formation illustrates the dysregulation of differentiation in tumorigenesis. The Wnt, Notch and Hedgehog (HH) pathways are developmental pathways that are commonly activated in many types of cancer. While substantial progress has been made in developing therapeutics targeting Notch and HH, the Wnt pathway has remained an elusive therapeutic target. This review will focus on the clinical relevance of the Wnt pathway in CSCs and tumor cell biology, as well as points of therapeutic intervention and recent advances in targeting Wnt/β-catenin signaling.

 


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 191